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Tripartite motif proteins are important viral restriction factors and affect processes ranging from uncoating to transcription to
immune signaling. Specifically, the promyelocytic leukemia protein (TRIM19; also called PML) is a viral restriction factor inhib-
iting processes from uncoating to transcription to cell survival. Here we investigated PML’s effect on adeno-associated virus
(AAV), a parvovirus used for gene delivery. Although dependovirus (AAV) and autonomous parvovirus (minute virus of mice)
replication centers can colocalize with PML, PML’s functional effect on parvoviruses is unknown. Using PML knockout mice, we
determined that PML knockout enhances recombinant AAV2 (rAAV2) transduction at a range of vector doses in both male and
female mice. In fact, male and female PML knockout mice exhibited up to 56-fold and 28-fold increases in transduction, respec-
tively. PML inhibited several rAAV serotypes, suggesting a conserved mechanism, and organ specificity correlated with PML ex-
pression. Mechanistically, PML inhibited rAAV second-strand DNA synthesis, precluding inhibition of self-complementary
rAAV, and did not affect the prior steps in transduction. Furthermore, we confirmed the effect of human PML on rAAV trans-
duction through small interfering RNA (siRNA)-mediated knockdown in HuH7 cells and determined that the highest level of
inhibition was due to effects of PML isoform II (PMLII). Overexpression of PMLII resulted in inhibition of second-strand syn-
thesis, vector production, and genome replication. Moreover, wild-type AAV2 production and infectivity were also inhibited by
PMLII, demonstrating a PML interaction with wild-type AAV. These data have important implications for AAV-mediated gene
therapy. Additionally, PMLII inhibition of AAV second-strand synthesis and replication, which are processes necessary for all
parvoviruses, suggests implications for replication of other parvoviruses.
Adeno-associated virus (AAV) is a helper-dependent memberof the Parvoviridae family, which, in addition to AAV, con-
tains other viruses of clinical and veterinary importance, such as
B19 parvovirus, human bocavirus, and canine parvovirus. AAV
consists of an icosahedral capsid surrounding a single-stranded
DNA genome carrying two genes, Rep and Cap, and has been
developed as a gene delivery vector for gene therapy applications.
For use as a vector or virus-like particle (recombinant AAV
[rAAV]), the viral genes can be removed and replaced with a
transgene cassette, with the terminal repeats being the only viral
elements required in cis (1). Although clinical rAAV-mediated
gene therapy has demonstrated increasing success in reaching ef-
ficacy goals, especially in restricted sites such as the eye (2), low
transgene expression or loss of expression over time has repeat-
edly compromised efficacy in other clinical trials (3, 4). Therefore,
efforts to increase the efficiency of rAAV transduction without
increasing the vector dose are imperative.
AAV’s replication pathway involves receptor-mediated endo-
cytosis, trafficking to the perinuclear region, nuclear entry, un-
coating, and second-strand DNA synthesis, followed by either
gene expression or persistence of episomal DNA (reviewed in ref-
erence 5). Because AAV evolved to infect cells in the presence of a
helper virus, it relies on these viruses, traditionally adenovirus
(Ad) or herpes simplex virus (HSV), for various processes in its
infection pathway. AAV helper virus functions range from
increasing the efficiency of intracellular viral trafficking (6) to in-
ducing AAV gene expression (7) to allowing cell escape (8). In
examining AAV biology, rAAV can be utilized to study the steps
in AAV production prior to replication, as it undergoes the same
transduction steps as wild-type AAV, through second-stand syn-
thesis, but cannot proceed with replication, making AAV a good
model for studying the initial transduction of parvoviruses with-
out the later steps of replication occluding the results.
The AAV helper viruses Ad and HSV share the ability to modify
or degrade the promyelocytic leukemia protein (PML). PML is a
member of the tripartite motif (TRIM) family of proteins, which
play a key role in both cell-intrinsic and immune host responses
against viruses (reviewed in reference 9). The antiviral mecha-
nisms of TRIM proteins range from that of TRIM5, which di-
rectly binds to incoming HIV-1 capsids, preventing uncoating
(10), to that of TRIM21, an intracellular antibody receptor which
causes proteasome-mediated degradation of antibody-bound vi-
rions (11), to regulation of pattern recognition receptor signaling
by at least eight different TRIMs (reviewed in reference 12). PML
(TRIM19) is an interferon-responsive protein involved in a wide
variety of cellular processes, including apoptosis, differentiation,
and antiviral defense. Various isoforms of PML are present in the
cytoplasm, nucleoplasm, and PML bodies (13). PML bodies,
punctate nuclear structures formed by a lattice of PML protein, act
as organizing centers for protein modifications and as depots for
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storage of key cellular proteins (14). PML inhibits infection by
many RNA and DNA viruses through a variety of diverse mecha-
nisms. These mechanisms include inhibition of vesicular stoma-
titis virus and human foamy virus transcription by PML isoform
III (15, 16), sequestration of HSV ICP0 in the cytoplasm by PMLIb
(17), sequestration of varicella-zoster viral capsids in a cage of
PMLIV (18), and activation of p53 and induction of apoptosis by
PMLIII in response to poliovirus (19). These mechanisms illus-
trate the breadth of viral families affected by PML and the range of
mechanisms by which they are affected.
To avoid PML antiviral activity, many viruses encode PML-
modifying proteins. For instance, Ad E4Orf3 binds directly to
PMLII and causes its rearrangement from spherical PML bodies to
tract-like structures (20, 21). Furthermore, HSV encodes ICP0, an
E3 ligase that causes proteasomal degradation of PML (22–24). In
a natural AAV infection, the PML-modifying properties of helper
viruses may protect AAV from any potential inhibitory effects of
PML. Moreover, not only have AAV replication centers been
shown to colocalize with PML tract-like structures in the presence
of Ad (25), but the replication centers of an autonomous parvo-
virus, minute virus of mice (MVM), have also been demonstrated
to colocalize with PML bodies during specific times in its replica-
tion cycle (26). However, the functional consequences of PML on
parvovirus transduction and replication have not been examined.
Therefore, we asked whether, in the absence of a helper virus, PML
is capable of inhibiting rAAV transduction. To address this ques-
tion, we utilized PML knockout mice, small interfering RNA
(siRNA)-mediated knockdown in human cells, and overexpres-
sion of PML isoforms. We demonstrated that PML inhibits the
transduction of rAAV both in vivo and in human cells in culture.
This inhibition is due to the prevention of second-strand synthe-
sis, and the majority of inhibition can be traced to PML isoform II.
PMLII can also inhibit the production of both rAAV and wild-
type AAV and infection by wild-type AAV. These data may lead to
strategies for enhancing the efficiency of rAAV-mediated gene
therapy. In addition, these data may have implications for the
other members of the parvovirus family.
MATERIALS AND METHODS
Cell culture and virus production. HEK293, HeLa, and HuH7 cells were
maintained in Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100
g/ml streptomycin at 37°C with 5% CO2. Adult mouse tail fibroblasts were
cultured in the medium described above supplemented with 1 mini-
mum essential medium (MEM) nonessential amino acids. AAV vectors
were produced through cesium gradient purification as described previ-
ously (27). Self-complementary rAAV and corresponding control vectors
were purified to yield pure virus as described previously (28). Wild-type
AAV was produced in the same way as rAAV, except that the plasmid
carrying AAV’s genes and the transgene cassette plasmid were replaced
with pSSV9. Virus and vectors were titrated by quantitative PCR (qPCR)
(27).
Isolation of adult mouse tail fibroblasts. Adult tail snip fibroblasts
were isolated using a protocol in the ENCODE database (http://genome
.ucsc.edu/ENCODE/protocols/cell/mouse/Fibroblast_Stam_protocol
.pdf). Briefly, tail snips were clipped into Hanks’ balanced salt solution
(HBSS; Life Technologies) and minced with a razor blade. The tissue was
then digested with collagenase type XI-S at a final concentration of 1,000
U/ml in HBSS for 30 min at 37°C. Tissue was washed once with HBSS,
resuspended in 0.05% trypsin-EDTA (Life Technologies), and incubated
at 37°C for 20 min. The tissue was then resuspended in complete growth
medium, pipetted to dissociate cells, and seeded in 35-mm plates with
tissue clumps under glass coverslips. The medium was changed every 4
days. When cells were subcultured, the cells were detached with 0.25%
trypsin-EDTA (Life Technologies) and seeded at ratios of 1:2 to 1:4.
Animals and in vivo transduction assays. All animal experiments
were conducted in accordance with the policies of the Institutional Ani-
mal Care and Use Committee at the University of North Carolina at Cha-
pel Hill. Wild-type 129/SV and PML knockout 129/SV-PMLtm1Ppp mice
(29) were a kind gift from Pier Paolo Pandolfi (Beth Israel Deaconess
Cancer Center). Age- and sex-matched mice were treated with the indi-
cated rAAV dose in phosphate-buffered saline (PBS) by retro-orbital in-
jection. Transduction from luciferase-encoding vectors was assayed by
live luciferase imaging (28). Transduction from green fluorescent protein
(GFP) vectors was determined using a GFP enzyme-linked immunosor-
bent assay (ELISA) kit (Cell Biolabs, Inc.). Briefly, livers were harvested at
7 days posttransduction and minced. A sample (approximately 50 mg)
was lysed with RIPA buffer and homogenized with a Tissue-Tearor (Bio-
Spec Products), and the total protein concentration was determined using
the Bio-Rad protein assay and a Bio-Rad SmartSpec Plus spectrophotom-
eter. Equal amounts of protein were used to proceed with the GFP ELISA
per the manufacturer’s directions. A Bio-Rad iMark plate reader was used
to determine absorbance, and pg GFP per mg total protein was calculated.
Biodistribution experiments and PML expression analysis. Mice
were treated with rAAV as described for transduction experiments, and
the specified organs were harvested and frozen on day 14 posttransduc-
tion. The organs were minced, and small samples were taken for luciferase
assay and vector genome quantification. Luciferase samples were lysed in
2 passive lysis buffer (Promega) and homogenized with a TissueLyser
(Qiagen) for 5 min at 40 Hz. The lysate was cleared by centrifugation, and
luciferase activity was assayed per the manufacturer’s instructions (Pro-
mega), using a Wallac1420 Victor2 plate reader. Protein levels were deter-
mined as described for transduction assays. Vector genome copy number
was determined by harvesting total DNA with a DNeasy Blood and Tissue
kit (Qiagen) and performing qPCR with equal volumes of DNA, as de-
scribed previously (28). For determination of in vivo PML expression, the
indicated organs were harvested, and 100-mg samples were immediately
stored in RNAlater (Qiagen) at 4°C. RNA was purified with TRIzol (Life
Technologies) per the manufacturer’s instructions. cDNA was synthe-
sized using a High Capacity cDNA reverse transcription kit (Life Technol-
ogies), and transcript levels relative to those of glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) were determined by qPCR.
qPCR protocols and primers. To determine PML expression levels
from cDNAs made from mouse tissues and from human cells, qPCR as-
says were designed using the Universal Probe Library Assay Design Center
(Roche). The amplicon was designed to be in the 5= region shared between
PML isoforms. For mouse tissues, the primers and probe for PML were as
follows: 5=-AGAGGAACCCTCCGAAGACT-3=, 5=-ATTCCTCCTGTAT
GGCTTGC-3=, and Mouse Universal Probe Library probe 76 (Roche).
The primers and probe for mouse GAPDH were as follows: 5=-GGGTTC
CTATAAATACGGACTGC-3=, 5=-CCATTTTGTCTACGGGACGA-3=,
and Mouse Universal Probe Library probe 52 (Roche). For human cells,
the primers and probe for PML were as follows: 5=-TTCTGCTCCAACC
CCAAC-3=, 5=-CGCTGATGTCGCACTTGA-3=, and Human Universal
Probe Library probe 5 (Roche). The primers and probe for human
GAPDH were as follows: 5=-ATCACTGCCACCCAGAAGACT-3=, 5=-AC
ACGGAAGGCCATGCCA-3=, and Mouse Universal Probe Library probe
34 (Roche). The qPCRs were run with LightCycler 480 Probes master mix
(Roche) in a Roche LightCycler 480 machine, using the following pro-
gram: 95°C for 10 min, 45 cycles of 95°C for 10 s, 60°C for 30 s, and 72°C
for 1 s (acquisition), and a final step at 40°C for 30 min. Standard curves
for each primer set were used to determine efficiency and to calculate
relative expression.
Entry, nuclear fractionation, and DNase protection assays. Mice
were treated as described for transduction experiments, and livers were
harvested at the indicated time points and placed immediately on ice.
Nuclear fractionation and DNase protection assays were performed as
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described previously (30), with slight modifications. After mincing, small
samples of liver tissue were taken and analyzed for total vector genome
copy number as described for biodistribution experiments. Ultracentrif-
ugation through a sucrose cushion was performed for 20 min. Nuclear
and DNase-protected DNAs were purified by use of a DNeasy Blood and
Tissue kit, with 5 g salmon sperm DNA (Life Technologies) added to
DNase-treated samples to act as a carrier. We determined the purity of
isolated nuclei to be 99.5%, using an EnzChek acid phosphatase assay
kit (Life Technologies).
siRNA and in vitro transduction assays. We used SMARTpool On-
TARGETplus PML siRNA (Thermo Scientific) to knock down human
PML and On-TARGETplus nontargeting control pool siRNA (Thermo
Scientific) as a negative control. HuH7 cells were seeded and transfected
with DharmaFECT per the manufacturer’s instructions, with slight mod-
ifications. HuH7 cells were transfected with 25 nM siRNA 48 h and 24 h
prior to transduction. At the time of transduction, the medium was
changed to contain the indicated dose of rAAV, and cells were incubated
for 24 h. Cells were harvested with 1 passive lysis buffer (Promega), and
luciferase and protein assays were performed as described above. Mouse
fibroblasts were seeded 16 h prior to transduction, and the medium was
changed to contain rAAV at the indicated dose at the time of transduction.
Transduction was assayed as described for siRNA experiments, at 48 h
posttransduction.
PML isoform plasmid backbone control and PMLII cloning. To gen-
erate a pEGFP-C3 backbone plasmid not containing a PML construct,
pEGFP-C3-PMLII was digested with BglII and BamHI (New England
BioLabs), and the 4.7-kb band was gel purified (Qiagen). This band was
self-ligated with T4 DNA ligase (New England BioLabs) and transformed
into XL10 Gold ultracompetent cells (Agilent Technologies), and colonies
were screened by digestion with AgeI and AvrII (New England BioLabs).
To clone the PMLII sequence into the pTR-ss-CMV-EGFP backbone,
pTR-ss-CMV-EGFP was digested with SalI (New England BioLabs), and
then the ends were blunted with Klenow DNA polymerase (New England
BioLabs). The DNA was purified with a PCR purification kit (Qiagen) to
remove the enzymes and buffers. The DNA was then digested with AgeI
(New England BioLabs), and a 4.2-kb band containing the plasmid back-
bone without the enhanced GFP (EGFP) gene was gel purified (Qiagen).
For retrieval of the PMLII DNA, the pEGFP-C3-PMLII plasmid was PCR
amplified with primers 5=-AAACCGGTCCATGGAGCCTGCACC-3=
and 5=-CCCTTCTCTTGTAACCTTGGAATTCGC-3= and with Illustria
RTG Hot Start mix (GE Healthcare). The PCR program was as follows:
95°C for 5 min, 30 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 120
s, 72°C for 5 min, and a hold at 4°C. The ends of the PCR product were
blunted with Klenow polymerase, PCR purified, and then digested with
AgeI. The 2.6-kb PCR product was then gel purified. The fragments were
ligated with T4 DNA ligase and transformed into electrocompetent
DH10B cells (Life Technologies), and colonies were picked based on se-
quence.
PML overexpression experiments. GFP-tagged overexpression con-
structs for PML isoforms I to VI were a kind gift from Peter Hemmerich
(Leibniz Institute for Age Research). The backbone plasmid was used as a
negative control. HeLa cells were transfected with PML plasmids at a 1:1
ratio with either pTR-CBA-Luc or salmon sperm DNA (Life Technolo-
gies). Briefly, HeLa cells were seeded in 24-well plates at 8  104 cells per
well 24 h prior to transfection. The cells were transfected by use of PEI
Max (Polysciences, Inc.) with a 1:1 ratio of the appropriate PML or back-
bone control plasmid (pEGFP-C3-PMLI, pEGFP-C3-PMLII, pEGFP-C1-
PMLIII, pEGFP-C1-PMLIV, pEGFP-C1-PMLV, pEGFP-C1-PMLVI, or
pEGFP-C3) and either pTR-CBA-Luc or salmon sperm DNA (Life Tech-
nologies). Total amounts used per well were 0.5 g total DNA and 3 l
PEI Max (1 mg/ml) in 50 l Opti-MEM (Life Technologies) added to 500
l complete growth medium. Transfection complexes were incubated for
10 min and then added to cells. Cells were incubated for 16 h, and then the
medium was changed to remove transfection reagents. Cells were trans-
duced at 24 h posttransfection. Cells were transduced with 500 vector
genomes (vg)/cell rAAV2-CBA-Luc at 24 h posttransfection, incubated
for 24 h, and assayed for transduction by luciferase assay. Luciferase values
from transduction were normalized to those from transfection. For the
self-complementary rAAV experiment, HeLa cells were seeded, trans-
fected with pTR-CMV-PMLII or pTR-CMV-Luciferase and carrier DNA,
and transduced with the indicated doses of single-stranded or self-com-
plementary rAAV2-CMV-EGFP at 24 h posttransfection. Transduction
was assayed at 24 h by flow cytometry (28).
Virus and vector production assays. For rAAV2 production experi-
ments, HEK293 cells were seeded onto 15-cm plates at a 1:3 density 24 h
prior to transfection (for 70% confluence at the time of transfection). For
transfection, pXX680 (12 g/plate), a pXR plasmid (10 g/plate), and a
pTR-CMV plasmid carrying either the PMLII gene or a reporter gene (6
g/plate) were combined with 520 l Opti-MEM (Life Technologies) and
110 l 1-mg/ml PEI Max (Polysciences, Inc.). The complexes were incu-
bated for 10 min at room temperature, and then the total volume was
added to the plates and cells were incubated for 48 h to allow vector
production. Cells were harvested, vector was purified as described above,
and vector was titrated by qPCR. For rAAV2 and wild-type AAV protein
level experiments and wild-type AAV production experiments, HEK293
cells were seeded at 1:3 in 10-cm plates 24 h prior to transfection. For
rAAV experiments, cells were transfected as described above with 4.8 g
of pXX680, 4 g of pXR2, and 2.4 g of either pTR-CMV-Luciferase or
pTR-CMV-PMLII in 208 l Opti-MEM and 44 l PEI Max. For wild-type
AAV2 experiments, cells were transfected as described above with 4.8 g
of pXX680, 4 g of pSSV9, and 2.4 g of either pEGFP-C3 or pEGFP-C3-
PMLII in 208 l Opti-MEM and 44 l PEI Max. Cells were incubated for
48 h to allow production. For wild-type AAV2 production, cells were
harvested and DNase treated as for virus production, and titers were mea-
sured by qPCR. Immunoblotting was performed as described previously
(31), with slight modifications. Samples of 150 g of protein were loaded
on 12% Mini-PROTEAN TGX precast polyacrylamide gels (Bio-Rad) and
electrophoresed at 225 V for 35 min in Tris-glycine-SDS buffer (Bio-Rad).
Proteins were transferred to a nitrocellulose membrane by use of an iBlot
apparatus (Life Technologies) on P3 for 4 min. AAV capsid proteins were
detected with B1 antibody, Rep proteins with IF11 antibody, GFP-PML
fusion constructs with Santa Cruz Biotech antibody sc-9996, and actin
with Abcam antibody ab8226.
Replication and infection assays. For rAAV DNA replication assays,
HEK293 cells were seeded at a 1:4 density into 10-cm plates 24 h prior to
transfection with PMLII or control plasmid. For transfection, 6 g of
pEGFP-C3 or pEGFP-PMLII was combined with 300 l DMEM without
FBS or antibiotics and 40 l PEI Max (Polysciences, Inc.) and incubated
for 10 min at room temperature. The entire volume was added to the
plate, and cells were incubated for 6 h. The medium was then changed to
remove the transfection reagents. Three days following transfection of the
PML overexpression plasmid or an EGFP expression plasmid, an addi-
tional transfection was performed to investigate rAAV replication. Three
plasmids were used in this PEI transfection: (i) the adenoviral helper plas-
mid XX680 (10 g); (ii) pXR2 (3 g), which supplies Rep2 and Cap2; and
(iii) the AAV vector plasmid (3 g) pITR2-CBA-luc. Three days following
the second transfection, Hirt DNA was isolated using a modified protocol
(32) and digested overnight with DpnI (New England BioLabs). Samples
were separated in an alkaline gel and transferred to a nitrocellulose mem-
brane (Amersham XL), and hybridization was performed with the prod-
uct of a random-primed labeling reaction (Roche), using the packaged
transgenic DNA sequence as the template (which also served as our size
standard) (27). Blots were exposed to film, and DNA quantitation of the
replication products was performed using ImageJ.
For wild-type AAV2 infection experiments, HEK293 cells were seeded
at 1:3 in 10-cm plates 24 h prior to transfection. The cells were transfected
as described before with 3 g pEGFP-C3 or pEGFP-C3-PMLII and 3 g
pXX680 or salmon sperm DNA in 300 l Opti-MEM and 40 l PEI Max.
Transfection cocktails were incubated for 10 min at room temperature,
and the total volume was added to the plates. The medium was changed to
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remove transfection reagents at 6 h posttransfection. At 24 h posttrans-
fection, the cells were concurrently seeded into 24-well plates at 1  105
cells/well and infected with the indicated dose of AAV2. Total DNA was
harvested at 48 h posttransduction by use of a DNeasy Blood and Tissue
kit, and numbers of viral genomes per cell were analyzed by qPCR.
Data analysis. We determined the statistical significance of all data by
using the nonparametric Kruskal-Wallis test and considered P values of
0.05 to be significant.
RESULTS
PML knockout enhances rAAV2 transduction in vivo. During
wild-type AAV’s natural life cycle, replicating AAV may be shel-
tered from the effect of PML by the PML-modifying activity of its
helper viruses. We hypothesized that PML may inhibit rAAV
transduction in environments where helper viruses are not pres-
ent. To test this hypothesis, we transduced wild-type (129/SV;
PML/) and PML knockout (129/SV-PMLtm1Ppp; PML/) mice
with a range of rAAV2-luciferase doses and examined transduc-
tion by live imaging. Although we observed very low levels of
transduction with 1  1010 vg/mouse, we observed expression of
luciferase in the area of the liver at day 11 posttransduction in
PML/ mice, whereas no expression was observable in PML/
mice (Fig. 1A). At a 5-fold higher dose of virus (5  1010 vg/
mouse), we observed transduction at the site of injection in
PML/ mice, although liver expression was still low; however,
liver and injection site expression was apparent in PML/ mice
(Fig. 1B). With 1  1011 vg/mouse, a commonly utilized dose of
AAV, transduction levels observed in PML/ mice were similar
to those seen with 5  1010 vg/mouse; however, PML/ mice
demonstrated increased levels of liver and injection site transduc-
tion (Fig. 1C). At a high dose of rAAV2 (5  1011 vg/mouse), we
observed high levels of transduction in all mice, but there was
more transduction in PML/ mice (Fig. 1D). By quantifying the
light output, we observed significant enhancements of transduc-
tion in PML/ mice compared to PML/ mice at all of the
tested doses for either total transduction (Fig. 1E) or transduction
in the area of the liver (Fig. 1F), demonstrating that knockout of
PML can enhance rAAV2 transduction and suggesting that PML
can inhibit rAAV2 transduction.
We performed the AAV dose experiment with female mice.
Because male mice have repeatedly been demonstrated to have
higher liver transduction levels than female mice (33), we more
thoroughly examined the effects of PML knockout in male and
female mice to determine whether the higher transduction levels in
male mice would override the effects of PML knockout. We trans-
duced male and female PML/ and PML/ mice with 2  1011
vg/mouse rAAV2 and assayed transduction by live imaging. For fe-
male mice, quantification demonstrated significantly enhanced
transduction in PML/ mice at both 7 days and 12 days posttrans-
duction (Fig. 1G). In fact, transduction was 28.2-fold higher at 7 days
and 18.6-fold higher at 12 days posttransduction. For male mice,
transduction was also significantly higher in PML/ mice, being
10.8-fold higher at 4 days and 56.4-fold higher at 11 days posttrans-
duction (Fig. 1H). These data demonstrate that PML causes signifi-
cant inhibition of rAAV2 transduction in vivo and that this effect can
be observed in both male and female mice.
Effect of PML knockout is conserved among several rAAV
serotypes. After determining that PML inhibited rAAV2 trans-
duction in vivo, we examined the transduction of various sero-
types of rAAV in PML/ mice to determine whether the trans-
duction pathway affected by PML is specific to rAAV2 or is
conserved among rAAV serotypes. Therefore, we transduced
PML/ and PML/ mice with 1  1011 vg/mouse rAAV6,
rAAV8, or rAAV9 and assayed transduction by live luciferase im-
aging. At 7 days posttransduction, we observed enhanced rAAV6
transduction in the area of the liver in PML/ mice (Fig. 2A) and
quantified this enhancement at 15.0-fold (Fig. 2B). In addition, we
observed higher transduction from rAAV8 (Fig. 2C) and quanti-
tated this increase at 47.0-fold at 3 days posttransduction (Fig.
2D). At 7 days posttransduction, the luciferase expression in
rAAV8-transduced PML/ mice saturated our imaging capabil-
ities even with very short exposures (data not shown). With
rAAV9, we observed increased transduction in PML/ mice at
day 7 posttransduction (Fig. 2E) and quantified this difference at
5.6-fold (Fig. 2F). Thus, these data demonstrate that PML knock-
out can enhance transduction of a number of rAAV serotypes,
suggesting that PML inhibits a process in AAV transduction that is
conserved between serotypes.
PML knockout enhances rAAV transduction in a manner
correlating to PML expression. To investigate further the en-
hancement of rAAV transduction we observed in PML/ mice,
we determined in which organs transduction was enhanced by
measuring transduction ex vivo. We transduced PML/ and
PML/ mice with rAAV2, harvested organs at 14 days posttrans-
duction, and measured luciferase activity and the vector genome
copy number. We observed significant increases in luciferase ac-
tivity from the liver (22.6-fold) and the kidney (9.2-fold); how-
ever, we observed no increase in activity in heart and lung tissues
and saw very little muscle transduction (Fig. 3A). In addition, we
observed no differences in rAAV2 genome copy number in any of
the organs tested (Fig. 3B). Although these data suggest that there
may be some organ specificity of the effect of PML on rAAV trans-
duction, rAAV2’s strong liver tropism hinders this conclusion.
Therefore, we investigated the effect of PML knockout on the
biodistribution of rAAV9, a systemic vector (34).
As with rAAV2, we transduced PML/ and PML/ mice
with rAAV9 and harvested tissues at 14 days posttransduction.
Similar to the case with rAAV2, we observed significant increases
in luciferase activity in the liver (3.9-fold), spleen (2.8-fold), and
kidney (5.2-fold) and no significant increases in heart, lung, and
muscle (Fig. 3C). In addition, the only significant changes in vec-
tor genome copy number observed were in the liver, where the
copy number was 3.5-fold higher in PML/ mice, and the lung,
where the copy number was 2-fold lower in PML/ mice (Fig.
3D). The smaller transduction enhancement observed with
rAAV9 at this time point than that observed with rAAV2 may be
due to the much greater transduction efficiency observed with
wild-type mice and rAAV9 vectors. To investigate the organ spec-
ificity of PML’s rAAV transduction enhancement further, we ex-
amined the expression of PML in PML/ mice by quantitative
reverse transcription-PCR (qRT-PCR). We observed the highest
levels of PML expression in the liver and spleen, intermediate
levels of expression in the kidney, low levels of expression in the
heart and lung, and very low levels of expression in the muscle
(Fig. 3E). Interestingly, we observed no increase in PML expres-
sion in the liver following rAAV2 transduction (data not shown),
suggesting that rAAV transduction does not induce PML tran-
scription. As the levels of PML expression appear to correlate with
the enhancement of rAAV9 transduction in PML/ mice that we
observed (Fig. 3C), this suggests that the organ specificity of the
PML enhancement observed occurred based on various PML ex-
Mitchell et al.
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FIG 1 PML knockout enhances rAAV2 transduction at several vector doses in both male and female mice. (A to D) Female PML/ and PML/ mice were
transduced with 1  1010 vg (A), 5  1010 vg (B), 1  1011 vg (C), or 5  1011 vg (D) rAAV2-CBA-luciferase and assayed by live luciferase imaging at 11 days
posttransduction (5-min exposure). (E and F) Light output from luciferase live imaging was quantified for either the whole mouse (E) or the area of the liver (F)
(n 	 3). (G and H) Female (G) and male (H) PML/ and PML/ mice were transduced with 2  1011 vg rAAV2-CBA-luciferase, transduction was assayed by
live luciferase imaging at two time points posttransduction, and light output from the whole mouse was quantified (5-min exposures for all, except males on day
11, for which the exposure was 1 min; n 	 5 for all groups except PML/ males, for which n 	 6). Data for individual mice are shown as diamonds, while the
bars indicate the means. *, P  0.05; **, P  0.01 versus PML/ mice.
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pression levels. Furthermore, our genome copy number data (Fig.
3B and D) suggest that changes in rAAV genome number are not
necessary for PML’s effect on rAAV transduction.
PML inhibits rAAV second-strand DNA synthesis. PML is
present in both the cytoplasm and nucleoplasm of cells and, addi-
tionally, forms PML nuclear bodies that organize posttransla-
tional modification of many proteins (9); therefore, it is possible
for PML to affect rAAV transduction directly or indirectly at many
transduction steps. To determine the step in rAAV transduction
that PML knockout affects, we transduced PML/ and PML/
mice with rAAV2 and harvested liver tissue at several times post-
transduction. We first asked whether the difference occurred in
cell entry by determining the vector genome copy numbers at 1
day and 7 days posttransduction. We observed no difference in
copy number between PML/ and PML/ mice at either time
point (Fig. 4A), suggesting that the effect of PML occurs postentry.
This agrees with our biodistribution data demonstrating no dif-
ference in rAAV2 vector genome copy number at 14 days post-
transduction (Fig. 3B). We next performed nuclear fractionation
to determine levels of nuclear entry at these time points. At both 1
day and 7 days, we observed equal numbers of nuclear vector
genomes in PML/ and PML/ mice (Fig. 4B), suggesting that
PML acts after rAAV2 nuclear entry. The next step in rAAV trans-
duction after nuclear entry is uncoating of the vector genome;
therefore, we assayed the numbers of uncoated genomes by per-
forming a DNase protection assay on our nuclear fractions. We
observed no difference in the numbers of unprotected (uncoated)
genomes between PML/ and PML/ mice (Fig. 4C), suggest-
ing that PML acts after this transduction step, on either second-
strand DNA synthesis or transcription.
To access whether PML knockout affects second-strand DNA
synthesis, we transduced PML/ and PML/ mice with self-
complementary and single-stranded rAAV8-EGFP and deter-
mined the transduction in harvested liver tissue at 7 days post-
transduction. Self-complementary rAAV genomes do not require
second-strand synthesis for transcription and thus should be un-
affected by inhibition of this step. As expected, with single-
stranded rAAV8, we observed a 7.9-fold transduction enhance-
ment in PML/ mice; however, we observed no difference in
transduction from self-complementary rAAV8 between PML/
and PML/ mice (Fig. 5A), suggesting that PML inhibits rAAV
second-strand DNA synthesis. To further substantiate this con-
clusion, we treated fibroblasts from the PML/ and PML/
mice with a wide range of rAAV2 doses to determine whether
there was a difference in the lower transduction threshold. We
hypothesized that transduction increases with PML knockout
might be greater at lower vector doses if PML affects second-
strand synthesis, as annealing of genomes could not compensate
FIG 2 Enhancement of rAAV transduction by PML knockout is conserved among several serotypes. Male PML/ and PML/ mice were transduced with 1 
1011 vg and assayed by live luciferase imaging. (A) Images of mice transduced with rAAV6-CBA-luciferase at 7 days posttransduction (30-s exposure). (B)
Quantification of light output from mice in panel A. (C) Images of mice transduced with rAAV8-CBA-luciferase at 3 days posttransduction (30-s exposure).
(D) Quantification of light output from mice in panel C. (E) Images of mice transduced with rAAV9-CBA-luciferase at 7 days posttransduction (30-s exposure).
(F) Quantification of light output from mice in panel E. Data for individual mice are shown as diamonds, while the bars indicate the means (n 	 3 for all groups
except PML/ rAAV6-transduced mice, for which n 	 4). *, P  0.05 versus PML/ mice.
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for a lack of second-strand synthesis. In fact, we observed trans-
duction in the 100-vg/cell group for PML/ cells but did not
observe transduction in the PML/ cells until the 500-vg/cell
group (Fig. 5B), demonstrating a lower threshold for transduction
in PML/ cells. These data also agree with our in vivo dosing data
showing a similar threshold at our lowest rAAV2 dose (Fig. 1A).
The differences in the threshold for transduction support our
mechanism of PML inhibition of rAAV second-strand DNA syn-
thesis. Taken together, our results demonstrate that PML knock-
out enhances second-strand DNA synthesis of rAAV vectors, sug-
gesting that PML can inhibit this transduction step.
Human PML inhibits rAAV transduction through the ac-
tions of PMLII. Our data to this point demonstrate the effect of
murine PML knockout on rAAV transduction. To confirm the
validity of our results for human PML, we used siRNA to knock
down PML in HuH7 cells, a hepatocellular carcinoma cell line,
and achieved 68% knockdown on an RNA level (data not shown).
We transduced cells with several doses of rAAV2-luciferase and
determined that knockdown approximately doubled rAAV2
transduction at all doses tested (Fig. 6A). Although this increase is
less than that observed in vivo, it is similar to that achieved in
primary fibroblasts harvested from mice at the higher vector doses
(Fig. 5B). Therefore, incomplete knockdown (data not shown)
and differences between in vitro and in vivo environments likely
account for the smaller effect of knockdown. Nevertheless, these
data confirm that human PML can inhibit rAAV transduction.
Human PML has at least seven major isoforms and a number of
minor isoforms, all of which share their N-terminal domains and
differ in their C-terminal domains (9). Of the major isoforms,
isoforms I through VI are nuclear (13) and could possibly mediate
the effect of PML on rAAV2 second-strand synthesis. We acquired
plasmids expressing EGFP-tagged versions of these nuclear iso-
forms (35), expressed them in HeLa cells (Fig. 6B), and examined
the effects of these isoforms on rAAV2 transduction. We deter-
mine that expression of five of the six isoforms (PMLI, PMLIII,
PMLIV, PMLV, and PMLVI) resulted in an approximately 2-fold
decrease in transduction, while expression of PMLII resulted in a
4.9-fold decrease in transduction (Fig. 6C). This greater effect of
PMLII than those of the other isoforms cannot be explained by
their relative levels of protein accumulation (Fig. 6B). To confirm
our in vivo mechanism, we then examined whether PMLII could
inhibit self-complementary rAAV2 transduction. In fact, al-
though we observed a significant decrease in the number of cells
transduced with single-stranded rAAV2 after PMLII overexpres-
sion, we observed significantly less inhibition of self-complemen-
tary rAAV2 transduction (Fig. 6D), confirming that human PML
isoform II is responsible for the inhibition of rAAV second-strand
synthesis.
PMLII overexpression inhibits rAAV2 and wild-type AAV2
production and replication. All of our data thus far addressed the
FIG 3 rAAV transduction enhancement is organ specific and correlates with PML expression. (A and B) PML/ and PML/ female mice were transduced with
2  1011 vg rAAV2-CBA-luciferase, and the indicated organs were harvested at 14 days posttransduction. Tissue was assayed for luciferase activity (A) and vector
genome copy number (vg/cell) (n 	 5) (B). Gray bars indicate the average values for two untransduced female mice. (C and D) PML/ and PML/ male mice
were transduced with 1  1011 vg rAAV9-CBA-luciferase, and the indicated organs were harvested at 14 days posttransduction. Tissue was assayed for luciferase
activity (C) and vg/cell (n 	 3) (D). Gray bars indicate values for an untransduced mouse. (E) The indicated organs were harvested from untransduced male
PML/ mice, and RNA was purified. PML expression relative to that of GAPDH was determined by qRT-PCR (n 	 3). Values are given as means with 1 standard
deviation (SD). RLU, relative light units. *, P  0.05; **, P  0.01 versus PML/ mice.
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role of PML in rAAV transduction; however, given our second-
strand synthesis mechanism, we set out to determine whether
PML plays a role in rAAV genome replication and virus produc-
tion. We began by examining the effect of PMLII overexpression
on virus production by encoding PMLII from a transgene in rAAV
vectors. We determine that the presence of the PMLII transgene
resulted in a 6.8-fold decrease in the yield of vector (Fig. 7A). As
the effect of PML on rAAV transduction was through second-
stand synthesis, we hypothesized that PMLII inhibits rAAV pro-
duction on the level of genome replication. Therefore, we per-
formed a replication assay to determine whether the level of
replicated DNA was lower in cells expressing PMLII than in cells
expressing a control vector. In fact, we observed slightly lower
levels of the replicative monomer and dimer forms of the vector
genome in PMLII-expressing cells (Fig. 7B), which were quanti-
fied at 73% of the control value (Fig. 7C). We then examined
whether PML could also inhibit the production of wild-type AAV
by producing wild-type AAV2 from an infectious clone, with or
without PMLII overexpression, and assaying the levels of virus
produced. As with rAAV2, we observed a 6.5-fold decrease in
wild-type AAV2 when PMLII was overexpressed (Fig. 7D), dem-
onstrating that PML also inhibits wild-type AAV2. We further
investigated this production effect with both wild-type and re-
combinant AAV by examining levels of the Rep and capsid pro-
teins. We observed greatly reduced levels of all three capsid pro-
teins, as well as the four Rep proteins, with PMLII overexpression
(Fig. 7E), although the degree of decrease varied. These data dem-
onstrate that PML can inhibit the production of both recombi-
nant and wild-type AAV on the protein level. Because utilizing an
infectious clone of AAV2 avoids the initial steps of AAV’s infec-
tious pathway and introduces high levels of template for the viral
genome, we then tested the effect of PMLII overexpression on the
infection of wild-type AAV by transfecting cells with PMLII and
the Ad helper plasmid, infecting them with AAV2, and determin-
ing the number of viral genomes produced. At 48 h postinfection,
we observed a large, significant inhibition of AAV2 replication in
the presence of PMLII (Fig. 7F), especially at low viral doses (60.1-
fold at 1 vg/cell and 1,207-fold at 0.1 vg/cell). We also observed
significant inhibition of AAV2 infection by PMLII at earlier time
points (data not shown), confirming PML’s inhibitory role in
AAV’s life cycle. Overall, our results demonstrate that PML can
inhibit the transduction of rAAV vectors in both human and mu-
rine contexts through the inhibition of second-strand DNA syn-
FIG 4 PML does not inhibit rAAV cell entry, nuclear localization, or uncoat-
ing. (A to C) PML/ and PML/ female mice were transduced with 1  1011
vg rAAV2-CBA-luciferase, and livers were harvested at the indicated times
posttransduction. (A) Total numbers of vg/cell were measured by qPCR (n 	
5). (B) Nuclei were isolated by subcellular fractionation, and numbers of nu-
clear vg/cell were measured by qPCR (n 	 5). (C) Nuclei were DNase digested
to completion, and numbers of remaining vg were determined. Numbers of
unprotected vg/cell were calculated (n 	 5). Gray bars indicate values for
untransduced mice (n 	 2). Values are given as means and 1 SD.
FIG 5 PML inhibits rAAV second-strand DNA synthesis. (A) PML/ and
PML/ female mice were transduced with 1  1011 vg single-stranded
rAAV8-CMV-GFP (ssAAV) or self-complementary rAAV8-CMV-GFP
(scAAV), and livers were harvested at 7 days posttransduction. Transduction
was determined by GFP ELISA (n 	 3). Gray bars indicate values for an un-
transduced mouse. (B) Adult mouse tail fibroblasts from PML/ and
PML/ mice were transduced with the indicated doses of rAAV2-CBA-lucif-
erase and assayed at 48 h by normalized luciferase assay. Fibroblast data rep-
resent three independent experiments. Values are given as means and 1 SD. *,
P  0.05 versus PML/ mice.
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thesis. Moreover, we traced this inhibition to human PMLII and
expanded the effect to the production of recombinant and wild-
type AAV and to wild-type AAV infectivity.
DISCUSSION
In this study, we examined the functional role of PML in the trans-
duction of AAV and in AAV production and infection in order to
determine whether PML can inhibit AAV. We determined that
PML inhibits rAAV transduction in vivo in a manner that corre-
lates with the PML expression level and that is conserved among
serotypes. Utilizing subcellular fractionation as well as self-com-
plementary rAAV, we demonstrated that the inhibition of rAAV
transduction by PML appears to occur at the level of conversion of
the single-stranded vector genome to a functional double-
stranded form. In addition, we established that human PML, es-
pecially PMLII, can also inhibit rAAV2 transduction and produc-
tion and wild-type AAV2 infection. To our knowledge, these data
represent the first time that a functional role for PML in the trans-
duction or replication of a parvovirus has been described.
Four pieces of data contribute to our conclusion that PML
inhibits rAAV second-strand DNA synthesis. (i) Equal numbers
of vector genomes completed the pre-second-strand synthesis
transduction steps of cell entry, nuclear entry, or uncoating in vivo
in PML/ and PML/ mice. (ii) Neither PML knockout in vivo
nor PML knockdown in human cells had an effect on self-com-
plementary rAAV transduction, which avoids second-strand syn-
thesis by self-annealing. (iii) Both in vitro and in vivo dose-re-
sponse curves demonstrated that a lower threshold rAAV dose was
required for successful transduction with PML/ mice, suggest-
ing a greater effect of PML at low vector doses where possible
annealing of vector genomes cannot compensate for a lack of sec-
ond-strand synthesis. (iv) Our rAAV DNA replication assay dem-
onstrated a small but significant decrease in rAAV genome repli-
cation when PML was overexpressed. Taken together, these data
provide strong evidence suggesting inhibition of rAAV second-
strand DNA synthesis by PML. Interestingly, in examining rAAV9
biodistribution, we observed an increase in vector genome copy
number with PML knockout specifically in the liver. Although this
apparent increase may be due to the very high transduction effi-
ciency of rAAV9 allowing a change in vector genome copy number
due to second-strand synthesis, this will require further investiga-
tion in the future.
PML affects the replication of many viruses through sequestra-
tion of viral components (17, 18) or prevention of transcription
(15, 16); however, we are not aware of any other studies demon-
strating a PML effect specifically on genome replication. AAV ge-
nome replication relies on the cellular replication machinery, in-
cluding DNA polymerase 
, replication factor C, proliferating cell
nuclear antigen, and replication protein A (RPA) (36, 37), al-
though second-strand synthesis has not been examined directly.
In the future, it will be interesting to investigate whether any of
these factors are involved in PML’s effect on rAAV second-strand
synthesis. Interestingly, RPA, through association with RPA inter-
acting protein  (RIP), is sequestered by PML (38); however, we
could find no evidence of a role for RPA in the inhibition of rAAV
transduction by PML (data not shown). We also could not observe
a direct interaction between PML and rAAV genomes or capsids
(data not shown). Resources such as a manually curated PML
FIG 6 Human PML, especially isoform II, inhibits rAAV transduction and second-strand synthesis. (A) HuH7 cells were transfected with PML or negative-
control siRNA 48 and 24 h prior to transduction with rAAV2-CBA-luciferase at the indicated dose. Transduction was assayed by luciferase assay at 24 h
posttransduction. Values are given as percentages of the negative-control value (Neg Cont) for the vector dose. (B) HeLa cells were transfected with the indicated
PML overexpression construct, and expression was analyzed by immunoblot analysis at 24 h posttransfection. GFP-PML fusion proteins were detected using a
GFP antibody. Constructs are shown in duplicate. Neg, nontransfected cells. The asterisk indicates a cellular band serving as a loading control. (C) HeLa cells were
transfected with the indicated PML overexpression or control plasmid 24 h prior to transduction with 500 vg/cell rAAV2-CBA-luciferase. Transduction was
assayed by luciferase assay at 24 h posttransduction and normalized to the value from transfection (Td:Tf). Values are given as percentages of the control
construct value. (D) HeLa cells were transfected with PMLII or control plasmid 24 h prior to transduction with either 1,000 vg/cell single-stranded rAAV2-
CMV-EGFP (ssAAV2) or 200 vg/cell self-complementary rAAV2-CMV-EGFP (scAAV2). At 24 h posttransduction, cells were assayed by flow cytometry. Values
given are percentages of cells transduced as fold values over that for the control plasmid group. Data represent three independent experiments. Values are given
as means and 1 SD. *, P  0.05 versus control; ‡, P  0.05 versus other isoforms.
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interactome (39) should facilitate the identification of factors
through which PML acts on rAAV transduction, as well as the
mechanism of PML’s effect. Moreover, as the same replication
factors are involved in MVM DNA replication as in AAV DNA
replication (40) and PML overexpression greatly inhibited AAV2
replication, it will be interesting to determine whether PML plays
a role in the second-strand synthesis and DNA replication of other
parvoviruses.
In addition to investigating the role of PML in rAAV transduc-
tion in vivo, we examined the effect of human PML on AAV in
order to eliminate the possibility that the PML effects were specific
to mice and determined that human PML could also inhibit rAAV
transduction. Furthermore, given that PML acted at a nuclear step
in transduction, we examined the six major nuclear human PML
isoforms and elucidated their effects on rAAV. We determined
that overexpression of five of the isoforms (I, III, IV, V, and VI)
caused a 2-fold decrease in rAAV2 transduction, while PMLII
caused a 5-fold decrease in transduction. Two possible hypotheses
could explain the partial effect of several isoforms and full effect of
one isoform: (i) PML proteins contain two domains important for
rAAV transduction inhibition, including one in the shared exons
(1 to 7a) and one in the unique region of PMLII; or (ii) the effect
on rAAV transduction is unique to PMLII, and overexpression of
other isoforms draws more endogenous PMLII into PML bodies
(35), where rAAV effects might occur. Further studies will deter-
mine which of these hypotheses is correct. Nevertheless, our data
clearly demonstrate that PMLII, and specifically its unique region,
is important for rAAV transduction inhibition.
The unique region of PMLII consists of the majority of exon 7b
and spans amino acids 571 to 824, i.e., the C terminus. Interest-
ingly, while PMLI and PMLII are the most abundant PML iso-
forms, the majority of known PMLII functions are interactions
with AAV’s helper viruses Ad and HSV. Specifically, Ad E4Orf3
binds within amino acids 645 to 674 of PMLII and rearranges it to
form tract-like structures (21). In addition, the conserved region 3
on Ad E1A-13S interacts with PMLII and may enhance viral and
cellular transcription (41). Furthermore, HSV has two distinct
mechanisms to decrease PMLII levels: ICP27-induced alternate
splicing (42) and degradation of PML by ICP0 (24). In fact, PMLII
expression decreases the replication of ICP0 null HSV (43). From
these studies, it is clear that PMLII plays an important role in DNA
virus replication that is still being elucidated. Further studies with
AAV may clarify the role of PML in both DNA virus replication
and other cellular processes.
Beyond rAAV transduction, we examined the effect of PML on
the production of rAAV and the production and infection of wild-
type AAV2. We observed similar decreases in production of wild-
type and recombinant AAV with PMLII overexpression and cor-
FIG 7 Production and replication of rAAV and AAV2 are inhibited by PMLII. (A) HEK293 cells were transfected for production of vector carrying either the
PMLII gene or a control gene (i.e., luciferase or EGFP gene). At 48 h posttransfection, vector was harvested and purified. The amount of vector produced was
determined by qPCR. Values indicate mean fold changes compared to the control transgene for three separate vector preparations, with standard errors of the
means (SEM). (B) HEK293 cells were transfected with PMLII or control plasmid 24 prior to transfection with viral production plasmids. At 72 h posttransduc-
tion, small-molecular-weight DNA was harvested. Replicative forms of rAAV DNA were detected by Southern blotting. No pXX680 lanes represent negative
controls for replication. M, monomer; D, dimer; LC, loading control (DpnI-digested plasmid). The image is representative of three trials on two blots. (C)
Monomer bands from the three trials for panel B were quantified by densitometry. Values given are means and 1 SD. (D) HEK293 cells were transfected with
PMLII or control plasmid (pXX680) and an AAV2 infectious clone. At 48 h posttransfection, virus was harvested and production was assayed by qPCR. Values
indicate mean fold changes compared to the control transgene for three separate vector preparations, with SEM. (E) HEK293 cells were treated as in panel A for
vector groups and as in panel D for virus groups. Protein was harvested at 48 h, and AAV capsid proteins (VP1, VP2, and VP3) and nonstructural proteins (Rep78,
Rep68, Rep52, and Rep40) were assayed by immunoblotting. Actin served as a loading control. The blot is representative of three independent experiments. (F)
HEK293 cells were transfected with pXX680 or carrier DNA and the PMLII or control plasmid 24 h prior to infection with the indicated dose of AAV2. AAV
genome copy number was determined by qPCR at 48 h postinfection. Data represent three independent experiments. Values given are means  1 SD. *, P  0.05
versus control.
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related this production defect with a small decrease in rAAV DNA
replication and a large decrease in viral protein levels. This inhi-
bition of AAV replication by PML raises the question of the role of
helper virus functions that affect PML in the replication of AAV.
Ad E4Orf3 binds to and rearranges PMLII (20, 21), while HSV
ICP0 causes proteasomal degradation of PML (22–24). Although
the PML-modifying activities of these proteins have not been
shown to provide helper virus functions (44), examining their
effects in the context of PML overexpression and in liver-derived
cell lines will be interesting in the future. In addition, with the
complicated regulation of AAV expression (45–49), it is unclear
whether the decrease in protein levels results from the decrease in
replication or an addition effect on the viral promoters. Given the
known effects of PML on viral transcription (15, 16), the act of
PML repressing AAV’s promoters would not be unprecedented.
We are currently further investigating the roles of genome repli-
cation and viral promoter activity in PML’s effect. Additionally,
we are investigating reversing this phenotype by knocking down
PML and possibly increasing vector yields, which would signifi-
cantly influence rAAV’s clinical applications.
In summary, we have demonstrated for the first time that PML
inhibits rAAV transduction in vivo through inhibition of second-
strand DNA synthesis. In addition, we demonstrated that human
PML can also inhibit rAAV2 transduction and production and
that PMLII is responsible for the majority of this effect. PMLII
inhibits wild-type AAV2 production and infection as well. Given
the large in vivo effect of PML on rAAV transduction, rAAV’s
interaction with PML will be important to target with rational
vector design as this pathway becomes better understood. Design-
ing vectors that avoid PML interactions could lead to large in-
creases in transduction, facilitating systemic gene therapy ap-
proaches. In conclusion, pursuing the interaction of AAV with
PML may have important implications for understanding AAV
biology, clinical vector production, enhancement of rAAV trans-
duction, and understanding the biology of other parvoviruses.
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